Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Cancer anorexia-cachexia syndrome (CACS) is associated with increased morbidity and mortality. Anamorelin is a novel, orally active ghrelin receptor agonist in clinical development for the treatment of CACS in NSCLC. The aim of this review is to summarize preclinical and clinical studies evaluating anamorelin as a potential promising treatment for CACS in NSCLC. AREAS COVERED: Pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability of anamorelin for the treatment of CACS in NSCLC were reviewed. Anamorelin administration may lead to increases in food intake, body weight and lean body mass, and a stimulatory effect on growth hormone secretion in NSCLC patients. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. EXPERT OPINION: Targeting ghrelin receptors presents the advantage of potentially addressing multiple mechanisms of CACS simultaneously including appetite, muscle protein balance, adipose tissue metabolism, energy expenditure and inflammation. Clinical data suggest that anamorelin is well tolerated and it effectively increases appetite, body weight and lean mass in patients with advanced NSCLC. Long-term safety remains unknown at this time. The potential synergistic effects of anamorelin with nutritional support or exercise as well as its efficacy/safety in other tumor types are also unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Cowley, M. A., Smith, R. G., Diano, S., Tschöp, M., Pronchuk, N., Grove, K. L., Strasburger, C. J., Bidlingmaier, M., Esterman, M., Heiman, M. L., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00063-1 · Cited by 1,679
Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
van der Lely, A. J., Tschöp, M., Heiman, M. L., & Ghigo, E. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0029 · Cited by 1,187
Expression of ghrelin receptor mRNA in the rat and the mouse brain
Zigman, J. M., Jones, J. E., Lee, C. E., Saper, C. B., & Elmquist, J. K. (2006) · The Journal of Comparative Neurology · doi:10.1002/cne.20823 · Cited by 1,074 · cited 1×
“In the CNS, its expression is highest in several discrete hypothalamic nuclei, including the anterior and lateral hypothalamic areas, and the ventromedial hypothalamus and arcuate nuclei [42,43].”
BackgroundGhrelin Strongly Stimulates Growth Hormone Release in Humans
Takaya, K., Ariyasu, H., Kanamoto, N., Iwakura, H., Yoshimoto, A., Harada, M., Mori, K., Komatsu, Y., Usui, T., Shimatsu, A., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7167 · Cited by 864 · cited 1×
“Ghrelin plays an important role in several physiological processes including increasing appetite by stimulating the production of orexigenic mediators such as neuropeptide Y [28,29], augmenting GH secretion, and by regulating energy balance through GH-independent mechanisms [26,30].”
BackgroundDobs, A. S., Boccia, R. V., Croot, C. C., Gabrail, N. Y., Dalton, J. T., Hancock, M. L., Johnston, M. A., & Steiner, M. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70055-x · Cited by 391
Garcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71154-4 · Cited by 218 · cited 1×
“The design of these trials was identical except that in one of them, patients enrolled in the 3-day crossover trial described above were allowed after a washout period of at least 5 half-lives; data from these two trials were pooled a priori [63].”
MethodSelf-citationGarcia, J. M., & Polvino, W. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-594 · Cited by 129
Self-citationGarcia, J. M., & Polvino, W. J. (2009) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2008.12.003 · Cited by 89 · cited 2×
“A robust increase in IGF-1 occurred after administration of the 50 and 75 mg doses of anamorelin [61].”
BackgroundSelf-citation
Cited by
Blauwhoff-Buskermolen, S., Versteeg, K. S., de van der Schueren, M. A. E., den Braver, N. R., Berkhof, J., Langius, J. A. E., & Verheul, H. M. W. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.6043 · Cited by 378
Katakami, N., Uchino, J., Yokoyama, T., Naito, T., Kondo, M., Yamada, K., Kitajima, H., Yoshimori, K., Sato, K., Saito, H., et al. (2018) · Cancer · doi:10.1002/cncr.31128 · Cited by 239
“Anamorelin (ONO-7643) is an orally active, highaffinity, selective agonist of the ghrelin receptor.(14,15) Previous phase 1 and 2 trials have demonstrated the safety and efficacy of anamorelin treatment for increasing body weight, lean body mass (LBM), and food intake.”
BackgroundAnamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis
Bai, Y., Hu, Y., Zhao, Y., Yu, X., Xu, J., Hua, Z., & Zhao, Z. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-016-3560-0 · Cited by 52
Currow, D. C., Maddocks, M., Cella, D., & Muscaritoli, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113471 · Cited by 27
“Anamorelin is a novel, orally active, highly selective non-peptide ghrelin analogue that has been shown to simultaneously target multiple components of cancer cachexia, including appetite, body composition, adipose tissue metabolism, energy expenditure, and inflammation [36,37].”
Background
Metadata
- Authors
- Zhang, H., & Garcia, J. M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2015-05-06
- Volume
- 16
- Issue
- 8
- Pages
- 1245-1253
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W1654990989
- Cited by
- 60
- References
- 9
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. https://app.cochat.ai/papers/10.1517/14656566.2015.1041500
- The paper
- Zhang, H., & Garcia, J. M. (2015). Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2015.1041500
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.